News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2023

31 May, 2023 Board director in Egetis Therapeutics acquires shares News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
23 May, 2023 Egetis announces termination of discussions regarding a potential acquisition of the Company and provides a corporate update News Corporate Information Other Corporate Information English Regulatory MAR IR Optional
27 April, 2023 Bulletin from Egetis Therapeutics’ Annual General Meeting 2023 News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
26 April, 2023 Interim report January-March 2023 News English Regulatory MAR Report Interim Q1 IR Optional
30 March, 2023 Egetis comments on market rumors News Corporate Action M&A English Regulatory MAR IR Optional
28 March, 2023 Egetis Therapeutics’ 2022 annual report published News English Regulatory VPML Report Annual IR Optional
24 March, 2023 Egetis continues to increase disease awareness about MCT8 deficiency News Corporate Information Other Corporate Information English IR Optional
23 March, 2023 NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL) News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
22 February, 2023 Year-end Report Q4 2022 News English Regulatory MAR Report Interim Yearend IR Optional
31 January, 2023 Change in the number of shares and votes in Egetis Therapeutics News Corporate Action Shares English Regulatory LHFI IR Optional
27 January, 2023 Egetis recruits Katayoun Welin-Berger as Vice President Operations News Corporate Information Staff change English IR Optional
25 January, 2023 Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 210 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional mfn-cus-disclaimer
24 January, 2023 Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 200 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional mfn-cus-disclaimer

2022

20 December, 2022 Egetis recruits Anny Bedard as President of Egetis North America News Corporate Information Staff change English IR Optional
7 December, 2022 Egetis submits Expanded Access Program for Emcitate® in the USA News Corporate Information Other Corporate Information English IR Optional
21 November, 2022 Egetis to participate at upcoming investor conferences News Corporate Information Other Corporate Information English IR Optional
18 November, 2022 Egetis continues to strengthen the commercial and medical affairs organizations for the expected launch of Emcitate® in 2024 News Corporate Information Other Corporate Information English IR Optional
8 November, 2022 Interim report January-September 2022 News English Regulatory MAR Report Interim Q3 IR Optional
25 October, 2022 Egetis presents Nomination Committee for the 2023 Annual General Meeting News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
17 October, 2022 Egetis announces detailed design for small, randomized, placebo-controlled trial for Emcitate for US NDA submission News Corporate Information Other Corporate Information English IR Optional
13 October, 2022 Egetis presents significant progress towards market at Capital Markets Day today News Corporate Information Presentation English IR Optional
6 October, 2022 Egetis’ Capital Markets Day on October 13: Agenda and Registration Details News Corporate Information Other Corporate Information English IR Optional
30 August, 2022 Egetis to participate at upcoming medical conferences News Corporate Information Other Corporate Information English IR Optional
23 August, 2022 Egetis to participate at upcoming investor conferences News Corporate Information Other Corporate Information English IR Optional
19 August, 2022 Interim report Q2 2022 News English Regulatory MAR VPML Report Interim Q2 IR Optional
PreviousNext

Calendar and upcoming reports

April 15, 2024
Annual Report 2023

May 3, 2024
Interim Report Q1 2024 (7:00am CEST)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com

Cookies
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept all”, you consent to the use of ALL the cookies. However, you may visit "Settings" to provide a controlled consent. Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
Save Accept all